Limits...
NAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammation.

Yamada T, Zuo D, Yamamoto T, Olszewski RT, Bzdega T, Moffett JR, Neale JH - Mol Pain (2012)

Bottom Line: The group II mGluR antagonist LY341495 blocked these effects of ZJ43 on the PAG and RVM.NAAG peptidase inhibition in the PAG and RVM did not affect the thermal withdrawal response in the hot plate test.Footpad inflammation also induced a significant increase in glutamate release in the PAG.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Biology, Georgetown University, Washington, DC, USA.

ABSTRACT

Background: Metabotropic glutamate receptors (mGluRs) have been identified as significant analgesic targets. Systemic treatments with inhibitors of the enzymes that inactivate the peptide transmitter N-acetylaspartylglutamate (NAAG), an mGluR3 agonist, have an analgesia-like effect in rat models of inflammatory and neuropathic pain. The goal of this study was to begin defining locations within the central pain pathway at which NAAG activation of its receptor mediates this effect.

Results: NAAG immunoreactivity was found in neurons in two brain regions that mediate nociceptive processing, the periaqueductal gray (PAG) and the rostral ventromedial medulla (RVM). Microinjection of the NAAG peptidase inhibitor ZJ43 into the PAG contralateral, but not ipsilateral, to the formalin injected footpad reduced the rapid and slow phases of the nociceptive response in a dose-dependent manner. ZJ43 injected into the RVM also reduced the rapid and slow phase of the response. The group II mGluR antagonist LY341495 blocked these effects of ZJ43 on the PAG and RVM. NAAG peptidase inhibition in the PAG and RVM did not affect the thermal withdrawal response in the hot plate test. Footpad inflammation also induced a significant increase in glutamate release in the PAG. Systemic injection of ZJ43 increased NAAG levels in the PAG and RVM and blocked the inflammation-induced increase in glutamate release in the PAG.

Conclusion: These data demonstrate a behavioral and neurochemical role for NAAG in the PAG and RVM in regulating the spinal motor response to inflammation and that NAAG peptidase inhibition has potential as an approach to treating inflammatory pain via either the ascending (PAG) and/or the descending pain pathways (PAG and RVM) that warrants further study.

Show MeSH

Related in: MedlinePlus

Reaction times of rats placed on a 52.5°C surface following injection of NAAG peptidase inhibitor into the PAG and RVM. Baseline latencies (O time) were established from 3 pretrial tests per animal and reaction times were assessed at different intervals after administration of saline or 150 μg ZJ43 into the PAG (n = 4, 6) and RVM (n = 4, 4).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3539905&req=5

Figure 8: Reaction times of rats placed on a 52.5°C surface following injection of NAAG peptidase inhibitor into the PAG and RVM. Baseline latencies (O time) were established from 3 pretrial tests per animal and reaction times were assessed at different intervals after administration of saline or 150 μg ZJ43 into the PAG (n = 4, 6) and RVM (n = 4, 4).

Mentions: Consistent with our previous reports that systemically administered ZJ43 and 2-PMPA failed to affect the thermal response latency [3,4], microinjection of ZJ43 (150 μg) into the PAG or RVM had no effect on the response in the hot plate test (Figure 8).


NAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammation.

Yamada T, Zuo D, Yamamoto T, Olszewski RT, Bzdega T, Moffett JR, Neale JH - Mol Pain (2012)

Reaction times of rats placed on a 52.5°C surface following injection of NAAG peptidase inhibitor into the PAG and RVM. Baseline latencies (O time) were established from 3 pretrial tests per animal and reaction times were assessed at different intervals after administration of saline or 150 μg ZJ43 into the PAG (n = 4, 6) and RVM (n = 4, 4).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3539905&req=5

Figure 8: Reaction times of rats placed on a 52.5°C surface following injection of NAAG peptidase inhibitor into the PAG and RVM. Baseline latencies (O time) were established from 3 pretrial tests per animal and reaction times were assessed at different intervals after administration of saline or 150 μg ZJ43 into the PAG (n = 4, 6) and RVM (n = 4, 4).
Mentions: Consistent with our previous reports that systemically administered ZJ43 and 2-PMPA failed to affect the thermal response latency [3,4], microinjection of ZJ43 (150 μg) into the PAG or RVM had no effect on the response in the hot plate test (Figure 8).

Bottom Line: The group II mGluR antagonist LY341495 blocked these effects of ZJ43 on the PAG and RVM.NAAG peptidase inhibition in the PAG and RVM did not affect the thermal withdrawal response in the hot plate test.Footpad inflammation also induced a significant increase in glutamate release in the PAG.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Biology, Georgetown University, Washington, DC, USA.

ABSTRACT

Background: Metabotropic glutamate receptors (mGluRs) have been identified as significant analgesic targets. Systemic treatments with inhibitors of the enzymes that inactivate the peptide transmitter N-acetylaspartylglutamate (NAAG), an mGluR3 agonist, have an analgesia-like effect in rat models of inflammatory and neuropathic pain. The goal of this study was to begin defining locations within the central pain pathway at which NAAG activation of its receptor mediates this effect.

Results: NAAG immunoreactivity was found in neurons in two brain regions that mediate nociceptive processing, the periaqueductal gray (PAG) and the rostral ventromedial medulla (RVM). Microinjection of the NAAG peptidase inhibitor ZJ43 into the PAG contralateral, but not ipsilateral, to the formalin injected footpad reduced the rapid and slow phases of the nociceptive response in a dose-dependent manner. ZJ43 injected into the RVM also reduced the rapid and slow phase of the response. The group II mGluR antagonist LY341495 blocked these effects of ZJ43 on the PAG and RVM. NAAG peptidase inhibition in the PAG and RVM did not affect the thermal withdrawal response in the hot plate test. Footpad inflammation also induced a significant increase in glutamate release in the PAG. Systemic injection of ZJ43 increased NAAG levels in the PAG and RVM and blocked the inflammation-induced increase in glutamate release in the PAG.

Conclusion: These data demonstrate a behavioral and neurochemical role for NAAG in the PAG and RVM in regulating the spinal motor response to inflammation and that NAAG peptidase inhibition has potential as an approach to treating inflammatory pain via either the ascending (PAG) and/or the descending pain pathways (PAG and RVM) that warrants further study.

Show MeSH
Related in: MedlinePlus